The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O’Sullivan, B. J.
Right arrow Articles by Thomas, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O’Sullivan, B. J.
Right arrow Articles by Thomas, R.
The Journal of Immunology, 2006, 176: 7278-7287.
Copyright © 2006 by The American Association of Immunologists

IL-1beta Breaks Tolerance through Expansion of CD25+ Effector T Cells1

Brendan J. O’Sullivan*, Helen E. Thomas{dagger}, Saparna Pai*, Pere Santamaria{ddagger}, Yoichiro Iwakura§, Raymond J. Steptoe*, Thomas W. H. Kay{dagger} and Ranjeny Thomas2,*

* Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia; {dagger} Department of Microbiology and Infectious Diseases, St. Vincent’s Centre for Medical Research, Julia McFarlane Diabetes Research Centre, Melbourne, Australia; {ddagger} Department of Microbiology, University of Calgary, Canada; and § Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Japan

IL-1 is a key proinflammatory driver of several autoimmune diseases including juvenile inflammatory arthritis, diseases with mutations in the NALP/cryopyrin complex and Crohn’s disease, and is genetically or clinically associated with many others. IL-1 is a pleiotropic proinflammatory cytokine; however the mechanisms by which increased IL-1 signaling promotes autoreactive T cell activity are not clear. Here we show that autoimmune-prone NOD and IL-1 receptor antagonist-deficient C57BL/6 mice both produce high levels of IL-1, which drives autoreactive effector cell expansion. IL-1beta drives proliferation and cytokine production by CD4+CD25+FoxP3 effector/memory T cells, attenuates CD4+CD25+FoxP3+ regulatory T cell function, and allows escape of CD4+CD25 autoreactive effectors from suppression. Thus, inflammation or constitutive overexpression of IL-1beta in a genetically predisposed host can promote autoreactive effector T cell expansion and function, which attenuates the ability of regulatory T cells to maintain tolerance to self.




This article has been cited by other articles:


Home page
Int ImmunolHome page
J. Hong, H. Li, M. Chen, Y. C. Q. Zang, S. M. Skinner, J. M. Killian, and J. Z. Zhang
Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis
Int. Immunol., December 1, 2009; 21(12): 1329 - 1340.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. Andre, D. F. Tough, S. Lacroix-Desmazes, S. V. Kaveri, and J. Bayry
Surveillance of Antigen-Presenting Cells by CD4+CD25+ Regulatory T Cells in Autoimmunity: Immunopathogenesis and Therapeutic Implications
Am. J. Pathol., May 1, 2009; 174(5): 1575 - 1587.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
B. B. Ganesh, D. M. Cheatem, J. R. Sheng, C. Vasu, and B. S. Prabhakar
GM-CSF-induced CD11c+CD8a--dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis
Int. Immunol., March 1, 2009; 21(3): 269 - 282.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Karumuthil-Melethil, N. Perez, R. Li, and C. Vasu
Induction of Innate Immune Response through TLR2 and Dectin 1 Prevents Type 1 Diabetes
J. Immunol., December 15, 2008; 181(12): 8323 - 8334.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
E. Akirav, J. A. Kushner, and K. C. Herold
{beta}-Cell Mass and Type 1 Diabetes: Going, Going, Gone?
Diabetes, November 1, 2008; 57(11): 2883 - 2888.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. C. Lewis, M. Mizrahi, M. Toledano, N. DeFelice, J. L. Wright, A. Churg, L. Shapiro, and C. A. Dinarello
{alpha}1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice
PNAS, October 21, 2008; 105(42): 16236 - 16241.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
P I Sidiropoulos, G Goulielmos, G K Voloudakis, E Petraki, and D T Boumpas
Inflammasomes and rheumatic diseases: evolving concepts
Ann Rheum Dis, October 1, 2008; 67(10): 1382 - 1389.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. J. P. M. Koenen, R. L. Smeets, P. M. Vink, E. van Rijssen, A. M. H. Boots, and I. Joosten
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells
Blood, September 15, 2008; 112(6): 2340 - 2352.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C. Brinster and E. M. Shevach
Costimulatory effects of IL-1 on the expansion/differentiation of CD4+CD25+Foxp3+ and CD4+CD25+Foxp3- T cells
J. Leukoc. Biol., August 1, 2008; 84(2): 480 - 487.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Watanabe, S. Gehrke, E. Contassot, S. Roques, J. Tschopp, P. S. Friedmann, L. E. French, and O. Gaide
Danger Signaling through the Inflammasome Acts as a Master Switch between Tolerance and Sensitization
J. Immunol., May 1, 2008; 180(9): 5826 - 5832.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
A. Kastbom, D. Verma, P. Eriksson, T. Skogh, G. Wingren, and P. Soderkvist
Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (The Swedish TIRA project)
Rheumatology, April 1, 2008; 47(4): 415 - 417.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. A. Rao, K. J. Tracey, and J. S. Pober
IL-1{alpha} and IL-1beta Are Endogenous Mediators Linking Cell Injury to the Adaptive Alloimmune Response
J. Immunol., November 15, 2007; 179(10): 6536 - 6546.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. O. Scumpia, M. J. Delano, K. M. Kelly-Scumpia, J. S. Weinstein, J. L. Wynn, R. D. Winfield, C. Xia, C. S. Chung, A. Ayala, M. A. Atkinson, et al.
Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis
Blood, November 15, 2007; 110(10): 3673 - 3681.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. R. Turnquist, G. Raimondi, A. F. Zahorchak, R. T. Fischer, Z. Wang, and A. W. Thomson
Rapamycin-Conditioned Dendritic Cells Are Poor Stimulators of Allogeneic CD4+ T Cells, but Enrich for Antigen-Specific Foxp3+ T Regulatory Cells and Promote Organ Transplant Tolerance
J. Immunol., June 1, 2007; 178(11): 7018 - 7031.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
X. Chen, O. M. Z. Howard, and J. J. Oppenheim
Pertussis Toxin by Inducing IL-6 Promotes the Generation of IL-17-Producing CD4 Cells
J. Immunol., May 15, 2007; 178(10): 6123 - 6129.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J.-B. Sun, S. Raghavan, A. Sjoling, S. Lundin, and J. Holmgren
Oral Tolerance Induction with Antigen Conjugated to Cholera Toxin B Subunit Generates Both Foxp3+CD25+ and Foxp3-CD25- CD4+ Regulatory T Cells
J. Immunol., December 1, 2006; 177(11): 7634 - 7644.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.